4th Quarter - Report
SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC
Client
Income
—
Expenses
$110,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S. 296, Preserving Access to Life Saving Medicines Act; H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act (ULTRA); Life Sciences Investment Act Issues relating to R&D funding for rare disease products, biosimilars and other products; end stage renal disease (ESRD) orphan drugs; reimbursements; drug shortages; DEA quotas; prescription drug user fees; exclusivity periods
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD BUCKLEY New | — |
| JOFF MASUKAWA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.